Company
Melbourne, VIC
Every investor coverage indicates participated in a round CERTA Therapeutics raised.
Investors whose own portfolio pages list CERTA Therapeutics, even though we haven't found any coverage of the round yet.
Companies CERTA Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Darren Kelly | CEO (former) | Brandon BioCatalyst |
Stories naming CERTA Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian biotech Certa Therapeutics reports Phase 2 scleroderma trial results for FT011 at a US rheumatology meeting, showing efficacy and safety, with a pivotal study planned.
Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily